基本信息
浏览量:1
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
个人简介
I have over 12 years of research experience studying infectious diseases, mainly focusing on virus-host interactions, pathogenesis, and developing vaccines and antivirals. My expertise revolves around studying biosafety level (BSL) 2+ and 3 pathogens such as human immunodeficiency virus (HIV), Enteroviruses, Zika virus (Flavivirus), and severe acute respiratory syndrome coronavirus 2 (Coronavirus).
My research focus includes understanding the virus-host interactions and vaccine-induced humoral, innate, and adaptive immune responses to evaluate the vaccine efficacy and to define the immune correlates of protection using preclinical in vivo animal models such as mice and non-human primates.
My research focused on studying Zika virus-host interactions and the development of host-directed broad antiviral therapeutics (Routhu NK, et al., The Journal of Neuroimmune Pharmacology, 2017 (Cover page); Routhu NK, et al., Molecular Pharmaceutics 2018; and Routhu NK, International Journal of Molecular Sciences, 2019). Additionally, my research was focused on developing a highly sensitive quantitative reverse transcription polymerase chain reaction (RT-qPCR)-based assay to quantify the frequency of cells producing multiply-spliced (ms)_SIV RNA in SIV-infected non-human primates (NHPs). This work aimed to understand the HIV-induced pathogenesis, characterize the HIV reservoirs, and determine the effect of HIV interventions (cure strategies) in macaque models (Frank I, et al., Nature Scientific Reports, 2019; Olwenyi OA, Routhu NK, et al., Cells, 2020).
Furthermore, my research primarily focused on designing DNA/ viral vector, Modified vaccinia Ankara (MVA)-based vaccines against Mycobacterium tuberculosis (M.tb) to generate robust antigen-specific T cell responses in the systemic and mucosal compartments, and I tested them in mouse models. Additionally, I played a major role in developing multiple vaccine candidates and vaccination approaches for coronavirus disease (COVID-19) using mice and monkey models of the disease. These studies aimed to improve the immunogenicity and protective efficacy of MVA-based vaccines against ancestral and emerging variants of SARS-CoV-2. This included optimizing the routes of immunization (intramuscular, intranasal, oral needle-free vaccination) to elicit broader humoral and T-cell responses against SARS-CoV-2 variants of concern (VOCs). I also focused on designing second-generation SARS-CoV-2 vaccines with broad antigen coverages to target multiple strains of SARS-CoV-2 and tested their immunogenicity and protective efficacy in mice and monkeys. My research demonstrated that MVA-based COVID-19 vaccines protect mice and rhesus macaques against SARS-CoV-2 WA-1/2020, Beta, and Delta isolates. Moreover, to address the challenge of increasing the durability of vaccine responses for COVID-19 vaccines, I showed that the novel SARS-CoV-2 RBD trimer protein-based vaccine in combination with either licensed adjuvant Alum or a potent TLR7/8 agonist (Alum/3M-052) induces robust neutralizing antibody responses and protects against SARS-CoV-2 challenge using mouse models. Furthermore, this vaccine also elicited strong humoral immune responses in monkeys and protected them from the pathogenic SARS-CoV-2 challenge (Routhu NK, et al., Immunity, 2021; Routhu NK, et al., Nature Communications, 2021; and Routhu NK, et al., Science Immunology, 2022).
My research focused on the "SARS-CoV-2 Assessment of Viral Evolution (SAVE)" study, which addresses the booster efficacy of FDA-approved Moderna’s mRNA-1273 and Novavax’s ancestral (NVX-CoV2373) or BA.1 (NVX-CoV2515) spike vaccines against SARS-CoV-2 BA.5 omicron infection in non-human primates. The findings from this study will likely have a positive impact on current vaccination strategies and public health efforts to combat infectious diseases (Routhu NK, et al., Science Immunology, 2023).
In summary, my diverse research experience and contributions have focused on critical aspects of infectious disease research, including virus-host interactions, vaccine development, and immune responses, particularly in the context of Zika virus, HIV, and COVID-19. These research findings have the potential to advance our understanding of infectious diseases and contribute to the development of effective vaccines and therapeutics for global health challenges.
研究兴趣
论文共 14 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
crossref(2024)
S. Govindaraj, H. Gao, V. Hans, N. Cheerdarla, L. S. Irby, S. Potlapalli, D. Endress,Nanda Kishore Routhu,Venkata S. Bollimpelli,Chris C. Ibegbu,A. S. Neish,David C. Montefiori,
引用1浏览0引用
1
0
biorxivpp.1-19, (2020)
Ines Frank,Arpan Acharya,Nanda K. Routhu,Meropi Aravantinou,Justin L. Harper,Stephanie Maldonado,Maria Sole Cigoli, Stanka Semova, Svetlana Mazel,Mirko Paiardini,Nina Derby,Siddappa N. Byrareddy,
加载更多
作者统计
#Papers: 14
#Citation: 213
H-Index: 7
G-Index: 11
Sociability: 5
Diversity: 3
Activity: 94
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn